Marker Therapeutics, Inc.

Marker is a clinical-stage immuno-oncology company developing novel T cell-based immunotherapies for hematological cancers and solid tumors. The company focuses on its Multi-Antigen Recognizing T cell platform, which expands natural, non-genetically modified tumor-specific T cells from blood to target multiple antigens simultaneously. Its pipeline features lead autologous candidate MT-601, evaluated for relapsed lymphoma and pancreatic cancer, and off-the-shelf candidate MT-401-OTS for acute myeloid leukemia and myelodysplastic syndromes. Marker serves patients with advanced cancer indications, particularly those with relapsed disease or limited alternatives.

Marker conducts clinical trials across multiple medical centers, including data gathered from seven sites across the United States for its lead lymphoma trial. The company collaborates with Baylor College of Medicine and third-party contract development and manufacturing organizations to support clinical manufacturing and scaling. Marker maintains its operational activities in the United States, though its text does not explicitly identify a specific headquarters city.

Summary of the business section of Marker Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 5 full-time employees: 1 clinical and 4 in administrative support.”